SAN DIEGO, CA/June 13, 2017 (STL.News) – A single dose of the glucagon-blocking drug REMD-477 can substantially reduce the amount of insulin needed and improve glucose levels without increasing hypoglycemia (low blood glucose levels) in patients with type 1 diabetes, according to the study, “REMD-477, a Human Glucagon Receptor (GCGR) Antibody, Reduces Daily Insulin Requirements […]

The post Glucagon-Blocking Drug Reduces Need for Insulin and Improves Blood Glucose Levels for Patients with Type 1 Diabetes appeared first on STL.News.